These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 8664192)

  • 1. Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: a European Cancer Centre (ECC) trial.
    Huizing MT; Vermorken JB; Rosing H; ten Bokkel Huinink WW; Mandjes I; Pinedo HM; Beijnen JH
    Ann Oncol; 1995 Sep; 6(7):699-704. PubMed ID: 8664192
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The pharmacokinetics and pharmacodynamics of high-dose paclitaxel monotherapy (825 mg/m2 continuous infusion over 24 h) with hematopoietic support in women with metastatic breast cancer.
    Papadopoulos KP; Egorin MJ; Huang M; Troxel AB; Kaufman E; Balmaceda CM; Vahdat LT; Hesdorffer CS
    Cancer Chemother Pharmacol; 2001; 47(1):45-50. PubMed ID: 11221961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer.
    Seidman AD; Tiersten A; Hudis C; Gollub M; Barrett S; Yao TJ; Lepore J; Gilewski T; Currie V; Crown J
    J Clin Oncol; 1995 Oct; 13(10):2575-81. PubMed ID: 7595709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The P-glycoprotein antagonist PSC 833 increases the plasma concentrations of 6alpha-hydroxypaclitaxel, a major metabolite of paclitaxel.
    Kang MH; Figg WD; Ando Y; Blagosklonny MV; Liewehr D; Fojo T; Bates SE
    Clin Cancer Res; 2001 Jun; 7(6):1610-7. PubMed ID: 11410497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose paclitaxel with granulocyte colony-stimulating factor in patients with advanced breast cancer refractory to anthracycline therapy: a European Cancer Center trial.
    Vermorken JB; ten Bokkel Huinink WW; Mandjes IA; Postma TJ; Huizing MT; Heimans JJ; Beijnen JH; Bierhorst F; Winograd B; Pinedo HM
    Semin Oncol; 1995 Aug; 22(4 Suppl 8):16-22. PubMed ID: 7543699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
    Klaassen U; Wilke H; Seeber S
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre.
    Huizing MT; Giaccone G; van Warmerdam LJ; Rosing H; Bakker PJ; Vermorken JB; Postmus PE; van Zandwijk N; Koolen MG; ten Bokkel Huinink WW; van der Vijgh WJ; Bierhorst FJ; Lai A; Dalesio O; Pinedo HM; Veenhof CH; Beijnen JH
    J Clin Oncol; 1997 Jan; 15(1):317-29. PubMed ID: 8996159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
    Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
    Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paclitaxel activity in anthracycline refractory breast cancer patients.
    Vici P; Di Lauro L; Conti F; Capomolla E; Gionfra T; Amodio A; Lopez M
    Tumori; 1997; 83(3):661-4. PubMed ID: 9267484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose-finding study and pharmacokinetics of epirubicin and paclitaxel over 3 hours: a regimen with high activity and low cardiotoxicity in advanced breast cancer.
    Conte PF; Baldini E; Gennari A; Michelotti A; Salvadori B; Tibaldi C; Danesi R; Innocenti F; Gentile A; Dell'Anna R; Biadi O; Mariani M; Del Tacca M
    J Clin Oncol; 1997 Jul; 15(7):2510-7. PubMed ID: 9215819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantification of paclitaxel metabolites in human plasma by high-performance liquid chromatography.
    Huizing MT; Sparreboom A; Rosing H; van Tellingen O; Pinedo HM; Beijnen JH
    J Chromatogr B Biomed Appl; 1995 Dec; 674(2):261-8. PubMed ID: 8788155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma.
    Edelman MJ; Meyers FJ; Houston J; Lauder I
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-68-S15-71. PubMed ID: 9346226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of paclitaxel and metabolites in a randomized comparative study in platinum-pretreated ovarian cancer patients.
    Huizing MT; Keung AC; Rosing H; van der Kuij V; ten Bokkel Huinink WW; Mandjes IM; Dubbelman AC; Pinedo HM; Beijnen JH
    J Clin Oncol; 1993 Nov; 11(11):2127-35. PubMed ID: 7901342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of 3-hour infusion of paclitaxel with or without granulocyte colony-stimulating factor in patients with advanced cancer.
    Schiller JH; Storer B; Tutsch K; Arzoomanian R; Alberti D; Feierabend C; Spriggs D
    J Clin Oncol; 1994 Feb; 12(2):241-8. PubMed ID: 7509380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Docetaxel in patients with anthracycline-resistant advanced breast cancer.
    Vici P; Belli F; Di Lauro L; Amodio A; Conti F; Foggi P; Gionfra T; Morelli MF; Botti C; Ferraironi A; Lopez M
    Oncology; 2001; 60(1):60-5. PubMed ID: 11150910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of Cremophor EL and genetic polymorphisms on the pharmacokinetics of paclitaxel and its metabolites using a mechanism-based model.
    Fransson MN; Gréen H; Litton JE; Friberg LE
    Drug Metab Dispos; 2011 Feb; 39(2):247-55. PubMed ID: 21056987
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update: the M.D. Anderson Cancer Center experience with paclitaxel in the management of breast carcinoma.
    Holmes FA
    Semin Oncol; 1995 Aug; 22(4 Suppl 8):9-15. PubMed ID: 7543702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I trial of a 96 h paclitaxel infusion with filgrastim support in refractory solid tumor patients.
    Socinski MA; Mudd PN; Radomski KM; Steagall A; Lawrence P; Bernard S; Letrent SP; Gonzalez P; Brouwer KL
    Anticancer Drugs; 1998 Aug; 9(7):611-9. PubMed ID: 9773805
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacologic study of 3-hour 135 mg M-2 paclitaxel in platinum pretreated patients with advanced ovarian cancer.
    Panday VR; Huizing MT; van Warmerdam LJ; Dubbelman RC; Mandjes I; Schellens JH; Huinink WW; Beijnen JH
    Pharmacol Res; 1998 Sep; 38(3):231-6. PubMed ID: 9782075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of paclitaxel administered in combination with cisplatin, etoposide and bleomycin in patients with advanced solid tumours.
    Nannan Panday VR; de Wit R; Schornagel JH; Schot M; Rosing H; Lieverst J; ten Bokkel Huinink WW; Schellens JH; Beijnen JH
    Cancer Chemother Pharmacol; 1999; 44(4):349-53. PubMed ID: 10447584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.